Skip to main content
. 2023 Jun 10;102(8):2137–2151. doi: 10.1007/s00277-023-05278-3

Fig. 1.

Fig. 1

Fig. 1

PFS distributions with 95% confidence intervals in a/ the overall population; b/ patients receiving IXA-Rd as second-line therapy or as third line therapy and beyond; c/ patients less than 80 years-old and of 80 years-old and more; d/ frail and non-frail patients